Portal and Mesenteric Vein Thromboses in a Patient With Prothrombin G20210 Mutation,Elevated Lipoprotein (a),and High Factor VIII

Abstract

A 65-year-old man was examined for abdominal pain. Portal and mesenteric vein thromboses were described by ultrasound and computed tomography. No local cause was found. The patient had a positive history of venous thromboembolism. Thrombophilia workup revealed prothrombin G20210A mutation (heterozygous), C677T mutation of methylenetetrahydrofolate reductase gene (homozygous), elevated level of lipoprotein (a), and high level of coagulation factor VIII. Anticoagulation was started and planned for a long-term duration. The etiology of portal vein thrombosis is often multifactorial, with various combinations of systemic factors (inherited or acquired prothrombotic conditions) and local precipitating factors (inflammation, injury to the portal venous system, cancer of the abdominal organs, cirrhosis). The reported prevalence of hypercoagulable states in patients with portal vein thrombosis has been very heterogeneous so far. Some authors support a role of the prothrombin G20210A mutation. In the reported patient, this mutation was revealed in a combination with other hypercoagulable states.

Keywords

portal vein thrombosis thrombophilia prothrombin gene mutation

References

Belfour GW , Stewart TG Case of enlarged spleen complicated by ascites, both depending upon varicose dilation and thrombosis of the portal vein. Edinburgh Med J. 1869;14:589-598.

Sobhonslidsuk A. , Reddy KR Portal vein thrombosis: a concise review. Am J Gastroenterol. 2002;97:535-541.

Bayraktar Y. , Harmanci O. Etiology and consequences of thrombosis in abdominal vessels. World J Gastroenterol. 2006;12:1165-1174.

Walker AP Portal vein thrombosis: what is the role of genetics? Eur J Gastroenterol Hepatol. 2005;17:705-707.

Treska V. , Daum O. , Ferda J. , Schutzova M. Idiopathic portal hypertension: a case report. Eur Surg. 2005;37:1-4.

Kocher G. , Himmelmann A. Portal vein thrombosis (PVT): a study of 20 non-cirrhotic cases. Swiss Med Wkly. 2005;135:372-376.

De Stefano V. , Fiorini A. , Rossi E. , et al. Incidence of the JAK2 V617F mutation among patients with splanchnic or cerebral venous thrombosis and without overt chronic myeloproliferative disorders. J Thromb Haemost. 2007;5:708-714.

Primignani M. , Barosi G. , Bergamaschi G. , et al. Role of the JAK2 mutation in the diagnosis of chronic myeloproliferative disorders in splanchnic vein thrombosis. Hepatology. 2006 ;44:1528-1534.

Bombeli T. , Basic A. , Fehr J. Prevalence of hereditary thrombophilia in patients in different venous systems . Am J Hematol. 2002;70:126-132.

10.

Janssen HLA , Meinardi JR , Vleggaar FP , et al. Factor V Leiden mutation, prothrombin gene mutation, and deficiencies in coagulation inhibitors associated with Budd-Chiari syndrome and portal vein thrombosis: results of a case-control study. Blood. 2000;96:2364-2368.

11.

Chamouard P. , Pencreach E. , Maloisel F. , et al. Frequent factor II G20210A mutation in idiopathic portal vein thrombosis. Gastroenterology. 1999;116:144-148.

12.

Primignani M. , Martinelli I. , Bucciarelli P. , et al. Risk factors for thrombophilia in extrahepatic portal vein obastruction. Hepatology. 2005;41:603-608.

13.

Frutos BMD , Fernandez HJA , Carrasco PM , et al. Portal-splenic-mesenteric venous thrombosis secondary to a mutation of the prothrombin gene. Gastroenterol Hepatol. 2005;28:329-332.

14.

Elhajj II , Salem ZM , Birjawi GA , et al. Heterozygous prothrombin 20210G/A mutation, associated with hyperhomocystenemia, and homozygous methylentetrahydrofolate reductase 677C/T mutation, in a patient with portal and mesenteric venous thrombosis. Hematol J. 2004;5:540-542.

15.

Mira Y. , Garcia del Castillo G. , Estelles A. , et al. Portal vein thrombosis associated to prothrombin G20210A mutation and protein C deficiency. Clin Appl Thromb Hemost. 2000;6:179-180.

16.

von Depka M. , Nowak-Göttl U. , Eisert R. , et al. Increased lipoprotein (a) levels as an independent risk factor for venous thromboembolism. Blood 2000;96:3364-3368.

17.

Crowther M. Lipoprotein (a): another risk factor for venous thrombosis? Am J Med. 2003;115:667-668

18.

Stein JH , Rosenson RS Lipoprotein (a) excess and coronary heart disease. Arch Intern Med. 1997;157: 1170-1176.

19.

Jürgens G. , Taddei Peters WC , Költringen P. , et al. Lipoprotein (a) serum concentration and apolipoprotein (a) phenotype correlate with severity and presence of ischemic cerebrovascular disease. Stroke. 1995;26: 1841-1848.

20.

Nowak-Göttl U. , Junker R. , Hartmeyer M. , et al. Increased lipoprotein (a) is an important risk factor for venous thromboembolism in childhood. Circulation . 1999;100:743-748.

21.

Marcucci R. , Liota AA , Cellai AP , et al. Increased plasma levels of lipoprotein (a) and the risk of idiopathic and recurrent venous thromboembolism. Am J Med. 2003;115:601-605.

22.

Vormittag R. , Vukovich T. , Stain M. , et al. Lipoprotein (a) in patients with spontaneous venous thromboembolism. Thromb Res. 2007;120:15-20.

23.

Egesel T. , Unsal I. , Bayraktar Y. Antiphospholipid antibodies and lipoprotein (a) as etiologic or contributory factors in patients with idiopathic cavernous transformation of portal vein . Turk J Gastroenterol. 2002;13:89-93.

24.

Kraaijenhagen RA , in `t Anker PS , Koopman MMW , et al. High plasma concentration of factor VIIIc is a major risk factor for venous thromboembolism . Thromb Haemost. 2000;83:5-9.

25.

Kyrle P. , Minar E. , Hirschl M. , et al. High plasma levels of factor VIII and the risk of recurrent venous thromboembolism. N Engl J Med. 2000 ;343:457-462.

26.

Kopacek Zilz C. , Keller Brenner J. , Elnecave RH Portal vein thrombosis and high factor VIII in Turner syndrome. Horm Res. 2006;66:89-93.

27.

Gunther R. , Folsch UR High plasma levels of factor VIII and von Willebrand factor in a patient with portal vein thrombosis. Z Gastroenterol. 2002 ;40:409-412.

28.

Webster GJM , Burroughs AK , Riordan SM Review article: portal vein thrombosis - new insight into aetiology and management. Aliment Pharmacol Ther . 2005;21:1-9.

29.

Malkowski P. , Pawlak J. , Michalowicz B. , et al. Thrombolytic treatment of portal thrombosis . Hepatogastroenterology. 2003;50:2098-2100.

30.

Klempnauer J. , Grothues F. , Bektas H. , Pichlmayr R. Results of portal thrombectomy and splanchnic thrombolysis for the surgical management of acute mesentericoportal thrombosis . Br J Surg. 1997;84:129-132.

31.

Blum U. , Haag K. , Rossle M. , et al. Noncavernomatous portal vein thrombosis in hepatic cirrhosis: treatment with transjugular intrahepatic portosystemic shunt and local thrombolysis . Radiology. 1995;195:153-157.

32.

Condat B. , Pessione F. , Denninger MH , et al. Recent portal or mesenteric venous thrombosis: increased recognition and frequent recanalization on anticoagulant therapy. Hepatology 2000;32:466-470.

33.

Condat B. , Pessione F. , Hillaire S. , et al. Current outcome of portal vein thrombosis in adults: risk and benefit of anticoagulant therapy. Gastroenterology 2001;120:490-497.

34.

Condat B. , Valla D. Nonmalignant portal vein thrombosis in adults. Nat Clin Pract Gastroenterol Hepatol. 2006;3:505-515.

35.

Sheen CL , Lamparelli H. , Milne A. , et al. Clinical features, diagnosis and outcome of acute portal vein thrombosis. QJM. 2000;93:531-534.

36.

Rahmouni A. , Mathieu D. , Golli M. , et al. Value of CT and sonography in the conservative management of acute splenoportal and superior mesenteric venous thrombosis. Gastrointest Radiol. 1992;17:135-140.

37.

Joh JH , Kim DI Mesenteric and portal vein thrombosis: treated with early initiation of anticoagulation . Eur J Vasc Endovasc Surg. 2005;29:204-208.

38.

Büller HR , Agnelli G. , Hull RD , et al. Antithrombotic therapy for venous thromboembolic disease. the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004;126:401S-428S.